Evaluating brain glucose metabolism in autoimmune encephalitis patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective cohort study aims to assess the diagnostic value of FDG PET imaging in 56 patients diagnosed with autoimmune encephalitis, either seropositive or seronegative, during the acute phase of their condition. Patients will be evaluated before the initiation of immunomodulating treatment or within 10 days of starting treatment, based on established diagnostic criteria. The study will also include a follow-up PET scan three months post-treatment to analyze changes in brain glucose metabolism. The goal is to determine if FDG PET can provide better diagnostic insights compared to traditional MRI methods.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥ 18 years old
* Newly diagnosed autoimmune encephalitis based on at least 1 of the 3 following criteria :

  1. " Definite limbic autoimmune encephalitis " according to 2016 Graus et al. criteria
  2. " Possible autoimmune encephalitis " according to 2016 Graus et al. criteria AND typical autoantibody detected in serum or CSF
  3. " Probable or certain paraneoplastic neurological syndrome " according to Graus et al. 2021 criteria (excluding peripheral neurological syndromes)
* Less than 6 months since first neurological symptoms imputable to autoimmune encephalitis
* Affiliated or entitled to a social security system (except AME)
* Obtaining free, written and informed consent (patient or legal representative or the close relative)

Exclusion criteria

* History of brain tumor, head trauma, infarction or cerebral hematoma likely to result in altered cerebral carbohydrate metabolism on PET
* Patients who hae been on immunotherapy (corticosteroid bolus, IVIg, plasma exchange, endoxan, rituximab or other immunotherapy) fr more than 10 days
* Pregnant or breast-feeding woman
* Ventilated intubated patient
* Absolute contraindication to MRI (Pacemaker, cochlear implant, etc.)
* Presence of cognitive disorders incompatible with goog cooperation with the PET scan
* Algic or agitated patient unable to remain immobile in supine position for 30 minutes
* Deprived of liberty or under a protective measure (guardianship or curatorship)
* Patient taking part in other interventional research involving radiopharmaceutical injections

Where it's running

• Hospital Pitie Salpetriere
  Paris, France Recruiting

Study contacts

• Principal investigator: Aurélie Kas, Pr — Hôpital Pitié Salpêtrière - Assistance Publique Hôpitaux de Paris
• Study coordinator: Aurélie Kas, Pr
• Email: aurelie.kas@aphp.fr
• Phone: 01 42 17 62 81

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Pregnant Women with Neuroimmune Diseases: A long-term follow-up study

  This study follows women with neuroimmune diseases and healthy controls through pregnancy and up to ten years to see how pregnancy affects disease activity and outcomes for both mother and baby.

  Recruiting Third Affiliated Hospital, Sun Yat-Sen University · Guangzhou, Guangdong · NCT07653984

• Identifying new autoantibodies and causes of autoimmune encephalitis

  This project looks for new autoantibodies and other disease features in adults with autoimmune encephalitis to help improve diagnosis and care.

  Recruiting Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Rome, RM · NCT07477015

• ART5803 for people with anti-NMDAR encephalitis or anti-NMDAR autoantibody–linked psychiatric disease

  This will test whether ART5803, a one‑armed antibody, is safe and can help adults with anti‑NMDAR encephalitis or anti‑NMDAR autoantibody‑associated psychiatric symptoms.

  Recruiting Phase 2 Arialys Australia Pty Ltd · Seoul · NCT07093333

• Universal CD19/BCMA CAR T-cell therapy for relapsed or refractory neurological autoimmune diseases

  This will test whether a single infusion of universal CD19/BCMA CAR T-cells given after chemotherapy helps adults with relapsed or refractory neurological autoimmune diseases who have CD19- or BCMA-positive B cells.

  Recruiting Early Phase 1 Tianjin Huanhu Hospital · Tianjin · NCT06939166

• Using Calculus Bovis Sativus to treat adult encephalitis

  This study is testing a traditional Chinese medicine called Calculus Bovis Sativus to see if it can help adults with autoimmune encephalitis feel better.

  Recruiting Tongji Hospital · Wuhan, Hubei · NCT06584045

• Identifying biomarkers for autoimmune diseases affecting the nervous system

  This study is trying to find specific markers in the blood of people with autoimmune diseases affecting the nervous system, like Multiple Sclerosis, to help with early diagnosis and better treatment options.

  Recruiting Tongji Hospital · Wuhan · NCT06502015

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.